BF-B — Brown-Forman Corporation

The post-earnings tone is mixed-not-ugly: revenue missed by roughly $7-10M, but EPS beat, gross margin expanded 40bp to 60.2%, organic operating income rose 4%, and management reaffirmed FY27 guidance. Sell-side coverage sits at Hold (5 Buy / 24 Hold / 7 Sell in the supplied breakdown), with average targets around $27.80-$28.10, implying only low-single-digit upside from $27.38.

Revenue has been flat-to-down for the better part of 12 quarters, oscillating between roughly $0.89B and $1.11B per quarter rather than compounding. TTM sales are about $3.91B and the latest quarter was down 1% YoY, pressured by Korbel termination, lower used-barrel sales, and soft tequila, partly offset by RTD growth. Earnings are noisier: the April 2026 quarter printed only $0.12 EPS versus $0.31-$0.57 in nearby quarters, which looks like a one-off/charge quarter, while July 2026 EPS of $0.38 returned to trend and grew 6% YoY. I read this as a cyclical bottom with early stabilization, not a structural collapse and not yet a confirmed recovery.

As of 2026-09-03, BF-B is historically cheap: TTM P/E of 17.78x versus a 5-year average of 27.33x, and P/S of 3.26x versus a 5-year average of 5.65x. Against the next-FY consensus EPS estimate of $1.704, the forward P/E is roughly 16x. The PEG ratio is not meaningful at -1.27 because trailing growth is negative, but for a 60.7% gross margin, 18.4% net margin, 13.3% ROIC business, 17.8x trailing and ~16x forward is not an expensive price; it just reflects the market treating Brown-Forman as a no-growth defensive.

The price embeds the modest consensus rebound already in estimates, not a growth boom. If EPS moves from $1.542 TTM to the $1.704 consensus, today's price is only about 16x forward earnings; even a modest 18x re-rating would put fair value near $30.70. If Q2 FY27 instead disappoints and estimates fall back toward $1.60, the same 16-17x multiple puts the stock in the mid-to-high-$20s with the $22.61 52-week low as the bearish floor. The stock is therefore priced for flat-to-slight improvement and will need actual volume evidence to re-rate much further.

As of 2026-09-03, RSI was 48.38, price was 1.72% below its 20-day SMA and only 0.46%/0.47% above its 50-day and 200-day SMAs. That is a range-bound, momentum-neutral picture rather than an overbought or oversold signal. The stock sits inside a $22.61-$31.92 52-week range, so the entry-timing implication is to wait for a clean break above the 20/50-day cluster or a retest closer to the low-$20s rather than chase the bounce.

• Global spirits volumes outside RTD remain flat-to-negative; premium whiskey and tequila are facing consumer wallet fatigue after years of price increases.
• RTD is the main category growth engine and is a genuine tailwind for Brown-Forman's New Mix and Jack Daniel's RTD franchise.
• Higher-for-longer interest rates and tighter consumer credit pressure discretionary spending, though BF-B's low beta and stable free cash flow make it defensive.
• FX and trade/tariff policy on U.S. spirits exports, especially into Europe, remain recurring headwinds to reported international sales.
• Supply-chain normalization and lapping of prior inventory rebalancing are stabilizing gross margins after the post-COVID distortion.

• Barclays Global Consumer Conference on September 9, 2026: management commentary on holiday pipeline builds and U.S. consumer takeaway could move the stock near-term.
• Q2 FY2027 earnings expected in early December 2026: the key evidence of whether the early U.S. recovery is real or just commentary.
• Gin Mare contingent earn-out resolution: a potential EUR 0-90M payout by July 2027 affects cash flow and sentiment, though not core operations.
• Further acceleration in RTD growth, led by New Mix and Jack Daniel's Tennessee Blackberry, would provide a visible earnings tailwind.

• Extended global spirits volume weakness, especially in premium American whiskey and tequila, would keep organic sales negative.
• EU tariffs, trade retaliation, or adverse FX on U.S. whiskey exports could pressure international margins.
• The one-off factors that produced the soft April 2026 quarter could recur if inventory rebalancing, charges, or category headwinds continue.
• A consumer trade-down to value spirits, beer, or wine would hurt the premium mix more than the headline revenue trend suggests.

At $27.38, BF-B is a hold, not a high-conviction buy or short. The balance sheet is strong, the dividend is well covered at 3.4%, and the stock is historically cheap, but revenue is flat and recent earnings growth is mostly cost-driven rather than volume-driven. I would not chase the bounce; I would add on weakness or after a quarter of confirmed organic volume stabilization.

Simplified normalized-owner-earnings DCF: normalized FCF of about $800M (between the $925M TTM FCF and roughly $638M three-year average, reflecting working-capital noise), 3.0% terminal growth, and a conservative 9.0% required return, divided by about 466M shares = $29.45. This is only modestly above the $27.38 market price, consistent with a fair-but-not-compelling risk/reward until volume growth returns.